The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Factors associated with delays in care of suspicious lung nodules at an academic medical center.
 
Nihar Rama
No Relationships to Disclose
 
Rachel Nordgren
No Relationships to Disclose
 
Aliya N. Husain
No Relationships to Disclose
 
Aditya Juloori
Consulting or Advisory Role - AquaLung Therapeutics; AstraZeneca; DaiichiSanko; EMDSerrono; General Electric; GlaxoSmithKline; Isoray; Regeneron
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - EMD Serono
 
Christine M. Bestvina
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb/Celgene; Daiichi Sankyo Nordics; EMD Serono; Gilead Sciences; Guardant Health; Mirati Therapeutics; Novocure; Tempus; Turning Point Therapeutics
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol Myers Squibb Foundation; Guardant Health
 
Rajat Thawani
No Relationships to Disclose
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Blueprint Pharmaceutic; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Medscape; MSD Oncology; Novartis; Oncohost; Pfizer; Regeneron; Revolution Medicines; Roche; Sanofi/Aventis; Takeda
Consulting or Advisory Role - Abbvie; Abion; AstraZeneca; Bayer; Bayer; Blueprint Medicines; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiiki Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Merck; Mirati Therapeutics; MSD Oncology
Research Funding - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - Merck
 
Septimiu Murgu
Consulting or Advisory Role - Boston Scientific; JJ Innovative Medicine; Olympus
 
Ajay Wagh
Honoraria - Medtronic
Speakers' Bureau - Biodesix
 
Douglas Kyle Hogarth
Consulting or Advisory Role - Biodesix; Boston Scientific; Noah Medical
 
Carrie Barth
No Relationships to Disclose
 
Darren Bryan
No Relationships to Disclose
 
Mark K. Ferguson
No Relationships to Disclose
 
Jessica Donington
Honoraria - AstraZeneca; BMS; Merck; Roche/Genentech
Consulting or Advisory Role - Amgen; AstraZeneca; BMS; Merck; Roche/Genentech
 
Maria Lucia Madariaga
No Relationships to Disclose